Lilly Gets FDA Approval for Eczema Drug Ebglyss

Eli Lilly and Company (LLY) announced that the FDA has granted approval to its IL-13 inhibitor Ebglyss (lebrikizumab) for treating moderate-to-severe atopic dermatitis, also called eczema. Ebglyss is approved for use in adults and children aged 12 and above who weigh at least 40 kgs and whose moderate-to-severe atopic dermatitis is not well controlled with topical prescription medicines.Ebglyss was approved in the European Union in 2023 and in Japan in January this year. The drug generated sales of $7.5 mil ...